Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $721000.0.

  • IDEAYA Biosciences' Depreciation & Amortization (CF) rose 2604.9% to $721000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 million, marking a year-over-year increase of 1311.27%. This contributed to the annual value of $2.7 million for FY2025, which is 1311.27% up from last year.
  • As of Q4 2025, IDEAYA Biosciences' Depreciation & Amortization (CF) stood at $721000.0, which was up 2604.9% from $661000.0 recorded in Q3 2025.
  • In the past 5 years, IDEAYA Biosciences' Depreciation & Amortization (CF) registered a high of $721000.0 during Q4 2025, and its lowest value of $382000.0 during Q1 2021.
  • Over the past 5 years, IDEAYA Biosciences' median Depreciation & Amortization (CF) value was $582500.0 (recorded in 2023), while the average stood at $569450.0.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 3175.07% in 2021, then tumbled by 984.37% in 2024.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Depreciation & Amortization (CF) stood at $448000.0 in 2021, then rose by 24.55% to $558000.0 in 2022, then increased by 12.72% to $629000.0 in 2023, then decreased by 9.06% to $572000.0 in 2024, then grew by 26.05% to $721000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $721000.0 in Q4 2025, compared to $661000.0 in Q3 2025 and $718000.0 in Q2 2025.